James Quigley
Stock Analyst at Goldman Sachs
(1.46)
# 3,495
Out of 4,996 analysts
23
Total ratings
75%
Success rate
-7.99%
Average return
Main Sectors:
Stocks Rated by James Quigley
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NVS Novartis AG | Downgrades: Sell | $119 → $118 | $123.65 | -4.57% | 2 | Sep 12, 2025 | |
| KYMR Kymera Therapeutics | Upgrades: Overweight | $49 → $79 | $56.25 | +40.44% | 6 | Jun 3, 2025 | |
| SNY Sanofi | Initiates: Neutral | $65 | $45.54 | +42.73% | 1 | Mar 21, 2025 | |
| GRFS Grifols | Maintains: Neutral | $10 → $11 | $9.82 | +6.92% | 1 | Dec 5, 2023 | |
| GLPG Galapagos NV | Maintains: Equal-Weight | $42 → $40 | $33.78 | +18.41% | 10 | Aug 7, 2023 | |
| EVO Evotec SE | Upgrades: Overweight | $12 → $16 | $3.48 | +359.77% | 3 | Jun 23, 2023 |
Novartis AG
Sep 12, 2025
Downgrades: Sell
Price Target: $119 → $118
Current: $123.65
Upside: -4.57%
Kymera Therapeutics
Jun 3, 2025
Upgrades: Overweight
Price Target: $49 → $79
Current: $56.25
Upside: +40.44%
Sanofi
Mar 21, 2025
Initiates: Neutral
Price Target: $65
Current: $45.54
Upside: +42.73%
Grifols
Dec 5, 2023
Maintains: Neutral
Price Target: $10 → $11
Current: $9.82
Upside: +6.92%
Galapagos NV
Aug 7, 2023
Maintains: Equal-Weight
Price Target: $42 → $40
Current: $33.78
Upside: +18.41%
Evotec SE
Jun 23, 2023
Upgrades: Overweight
Price Target: $12 → $16
Current: $3.48
Upside: +359.77%